Keeney Adam 4

What Happened
Adam Keeney, Head of Corporate Development at Biogen Inc. (BIIB), was granted 8,025 restricted stock units (RSUs) on February 13, 2026. The award was recorded as an "A" (award/grant) on the Form 4 with an acquisition price of $0.00 — no cash was paid. These are derivative awards that will convert into shares as they vest.

Key Details

• Transaction date: February 13, 2026; Form 4 filed February 17, 2026 (appears timely).
• Grant: 8,025 RSUs; acquisition price reported $0.00 (award).
• Vesting: RSUs vest in three equal yearly installments beginning on the first anniversary of the grant (first vesting expected Feb 13, 2027).
• Shares owned after transaction: not specified in the provided filing excerpt.
• No indication in the provided data of a 10b5-1 plan, sale, tax withholding, or late filing.

Context
RSUs are a form of equity compensation that deliver shares (or cash equivalent) when they vest; they are not an open-market purchase or sale and therefore do not directly signal buying or selling sentiment. Grants are common for employee compensation and retention; retail investors should view this as standard executive compensation unless accompanied by other material actions or disclosures.